Akebia Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Akebia Therapeutics (AKBA).

Price Target Range — 10 Quarters

Analyst Consensus — 6 Analysts

5Buy

1Hold

Consensus RatingBuy# Analysts6Avg. Consensus PT$5Upside to Avg. PT+447.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

Visualizza tutte le valutazioni →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 15, 2026	BTIG	Julian Harrison	Maintained	Buy	$4
Sep 8, 2026	WestPark Capital	Ed Arce	Initiate	Buy	$5
Aug 7, 2026	Leerink Partners	Roanna Ruiz	Downgrade	Outperform→Market Perform	$1
Jul 1, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$6
Apr 7, 2026	BTIG	Julian Harrison	Maintained	Buy	$4
Feb 25, 2026	BTIG	Julian Harrison	PT Cut	Buy	$5→$4
Feb 6, 2026	Piper Sandler	Allison Bratzel	PT Cut	Overweight	$6→$4
Feb 6, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$6
Dec 2, 2025	BTIG	Julian Harrison	Maintained	Buy	$5
Dec 2, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$6
Oct 30, 2025	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$8→$6
Oct 29, 2025	BTIG	Julian Harrison	PT Cut	Buy	$10→$5
Jun 4, 2025	HC Wainwright & Co.	Matthew Caufield	Assumes	Buy	$8
Apr 28, 2025	Leerink Partners	Roanna Ruiz	Initiate	Outperform	$7
Apr 4, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Apr 1, 2025	Jefferies	Roger Song	Initiate	Buy	$6
Mar 14, 2025	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$4→$6
Mar 14, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Jan 23, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Jan 14, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.

Benzinga Newsdesk

PRO
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5

WestPark Capital analyst Ed Arce initiates coverage on Akebia Therapeutics (NASDAQ:AKBA) with a Buy rating and announces Price Target of $4.5.

Benzinga Newsdesk

PRO
Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target

Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

HC Wainwright & Co. analyst Matthew Caufield reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $6 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

BTIG analyst Julian Harrison reiterates Akebia Therapeutics (NASDAQ:AKBA) with a Buy and maintains $4 price target.

Benzinga Newsdesk

Where Akebia Therapeutics Stands With Analysts

Benzinga Insights

Akebia Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Akebia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

PRO
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5

PRO
Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

PRO
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

Where Akebia Therapeutics Stands With Analysts

People Also Watch

People Also Watch

Akebia Therapeutics Inc

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

Akebia Therapeutics Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROBTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

PROWestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5

PROLeerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target

PROHC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

PROBTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

Where Akebia Therapeutics Stands With Analysts

People Also Watch

People Also Watch

PRO
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target

PRO
WestPark Capital Initiates Coverage On Akebia Therapeutics with Buy Rating, Announces Price Target of $4.5

PRO
Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target

PRO
HC Wainwright & Co. Reiterates Buy on Akebia Therapeutics, Maintains $6 Price Target

PRO
BTIG Reiterates Buy on Akebia Therapeutics, Maintains $4 Price Target